NCT06991920View on ClinicalTrials.gov

Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage

NANot yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 1, 2030

Study Completion Date

April 1, 2032

Conditions
Adult ALLMPAL
Interventions
DRUG

Blinatumomab

CD19-positive, Ph+ patients with favorable financial status may receive VP + TKI + blinatumomab therapy；CD19-positive, Ph- patients with favorable financial status may receive VCP + blinatumomab therapy.

DRUG

Venetoclax

CD19-positive, Ph+ patients with poor financial status may receive VP + TKI + VEN therapy；CD19-negative or CD19-positive, Ph- patients ineligible for blinatumomab may receive VPCLP + VEN therapy.

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06991920 - Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage | Biotech Hunter | Biotech Hunter